PURE Bioscience Q2 net product sales $325K, net loss $1.0M; shifting to distributor model

PURE BIOSCIENCE, INC.

2024-Q2 EPS reported -$0.01 revenue$1,043,000

Net product sales $325K in Q2 FY2024, down 18% from $396K YoY; net loss $1.002M vs $1.060M.
Q2 net loss per share ($0.01); six-month net product sales $1.043M, up 21% from $863K.
CEO cites unexpected interruption in product flow to one major customer as cause of revenue shortfall.
Company shifting from direct sales to distributor model to expand market coverage and accelerate growth.
New food segments and dairy/animal health show interest; registered to exhibit at IAFP July 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PURE BIOSCIENCE, INC. reported the fiscal second quarter ended January 31, 2024 results: revenue $325,000, net income $1,002,000, EPS ($0.01) per share.

Period: the fiscal second quarter ended January 31, 2024
Revenue: $325,000
Net income: $1,002,000
EPS: ($0.01) per share
Result: reported results

Exact text from the filing

Net product sales were $325,000 and $396,000 for the fiscal second quarter ended January 31, 2024 and 2023, respectively. The decrease of $71,000 was attributable to decreased sales across our end user network. ● Net loss for the fiscal second quarter ended January 31, 2024 was $1,002,000, compared to $1,060,000 for the fiscal second quarter ended January 31, 2023. ● Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2024 was $938,000, compared to $993,000 for the fiscal second quarter ended January 31, 2023. ● Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2024 and 2023, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PURE BIOSCIENCE, INC. reported the six months ended January 31, 2024 results: revenue $1,043,000, net income $1,737,000, EPS ($0.02) per share.

Period: the six months ended January 31, 2024
Revenue: $1,043,000
Net income: $1,737,000
EPS: ($0.02) per share
Result: reported results

Exact text from the filing

Net product sales were $1,043,000 and $863,000 for the six months ended January 31, 2024 and 2023, respectively. The increase of $180,000 was attributable to increased sales across our end user and distribution network. ● Net loss for the six months ended January 31, 2024 was $1,737,000, compared to $2,053,000 for the six months ended January 31, 2023. ● Net loss, excluding share-based compensation, for the six months ended January 31, 2024 was $1,593,000, compared to $1,842,000 for the six months ended January 31, 2023. ● Net loss per share was ($0.02) for the six months ended January 31, 2024 and 2023, respectively.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

PURE BIOSCIENCE, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-010300

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.